NCT05189717: A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

NCT05189717
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain metastasis or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT05189717

Comments are closed.

Up ↑